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Highlights 29 
? Transversal psoas thickness index (TPTI) is measured on an umbilicus-targeted CT. 30 
? TPTI was independently associated with mortality.  31 
? TPTI is easy, quick, cheap, and highly reproducible, reliable by a non-expert operator.  32 
? TPTI could be a marker of muscle mass and function. 33 
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ABSTRACT  55 
Objective: Malnutrition impairs prognosis in liver cirrhosis. Aims: to determine: if transversal 56 
(TPTI) and axial (APTI) psoas thickness indices predict mortality in cirrhotic patients; feasibility 57 
and reproducibility of psoas muscle transversal (TDPM) and axial (ADPM) diameters 58 
measurements. Research Methods & Procedures: Retrospective study. Inclusion criteria: 59 
cirrhosis on liver transplantation waiting list, abdominal CT scan within the three months60 
preceding list inscription. TDPM and ADPM were measured on a single umbilicus-targeted CT 61 
image by non-expert and expert operators. TPTI or APTI (mm/m) were calculated as: TDPM or 62 
ADPM/height (m). Statistics: mortality prediction and associated variables: area under the 63 
receiver operating characteristic curve (AUC) and Cox proportional hazard models assessed. 64 
TPTI and APTI interobserver agreement: kappa (k) correlation test. Results: 173 patients were 65 
included. Low TPTI was associated with increased mortality: AUC=0.66 [95% confidence 66 
interval, 0.51‒0.80]. TPTI was the only factor associated with mortality (hazard ratio=0.87, 95%67 
confidence interval 0.76–0.99, P=0.034). There was an almost perfect interobserver agreement 68 
between the two operators: TDPM, k=0.97; ADPM, k=0.94; P<0.0001. Conclusion(s): TPTI 69 
measured on umbilicus-targeted CT scan before inscription on waiting-list for liver 70 
transplantation predicts mortality of cirrhotic patients. TPTI measurement is easy and reliable, 71 
even by a non-trained operator, then highly feasible in the daily clinical practice.72 
73 
Keywords: muscle mass; malnutrition; computed tomography scan; liver failure74 
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INTRODUCTION75 
Chronic liver diseases are often complicated with malnutrition [1], that impairs the prognosis76 
[2,3]. Nevertheless, because of rapid fluid shifts and altered water compartmentalization due to 77 
ascites and oedema, standard methods of nutritional assessment (weight loss, body mass index,78 
biological markers, i.e. albumin, transthyretin, or multicomposite scores) are not usable. Also, 79 
body composition assessment methods, such as bioimpedance analysis (BIA) or dual-energy X-80 
ray absorptiometry (DEXA) [4,5] are not applicable to patients with liver cirrhosis (BIA) [6], or 81 
not routinely applicable in the daily clinical practice (DEXA) [7]. Liver cirrhosis is associated 82 
with significant changes in body composition: the prevalence of muscle mass loss is estimated to83 
be 20-60% [8,9]; muscle mass loss is an independent prognostic factor in cirrhosis [10]. Mid-arm 84 
muscle circumference is an independent predictor of survival in patients with liver cirrhosis [11],85 
but its interobserver variability limits its use in the daily practice. In the last decade, the 86 
development of cross sectional imaging techniques, such as computed tomography (CT) or 87 
magnetic resonance imaging (MRI) [12], is very promising to assess muscle mass. Developed 88 
from studies conducted in oncology [13], disease prognosis could be assessed by the whole 89 
muscle cross sectional area measured on a third lumbar vertebra (L3)-targeted CT normalized by 90 
height. This L3 skeletal muscle index predicted mortality after liver transplantation [14-16], and91 
recently in cirrhotic patients on waiting-list for liver transplantation [17,18]. However this 92 
technique could be time-consuming. Therefore there is a need to develop simpler and easier 93 
methods to assess muscle mass, doable for all in the daily clinical practice. Psoas muscle 94 
measurement could appear as a reliable marker to assess cirrhosis prognosis. Recently, Golse et 95 
al suggested that psoas muscle area better predicts post-liver transplantation 1-year survival than96 
L3 skeletal muscle index, but they did not assess the predictive role of transversal psoas muscle 97 
thickness [19]. Durand et al showed that the measurement of the transversal psoas muscle 98 
thickness by CT images targeted on the umbilicus, standardized to height, was an independent 99 
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predictive factor for mortality in cirrhotic patients with refractory ascites on waiting-list for liver 100 
transplantation [20]. However these results were never confirmed by an independent study, nor 101 
in a whole population of cirrhotic patients on waiting-list for liver transplantation. Therefore, the 102 
main aim of this retrospective study was to determine whether the measurement of the 103 
transversal or axial diameter of the psoas muscle on an abdominal CT predicted mortality in 104 
patients with cirrhosis on waiting-list for liver transplantation. The secondary aims were to105 
determine the feasibility and reliability of the measurements of transversal or axial psoas muscle106 
diameters by a non-trained operator.107 
108 
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METHODS 109 
Study design 110 
A monocentric observational retrospective study was conducted in the Department of Liver 111 
Transplantation and the Hepatic diseases Unit of the Rennes University Hospital (CHU Rennes), 112 
Rennes, France. Our unit is a tertiary referral centre for liver transplantation in France. 113 
 114 
Patients’ recruitment115 
All patients with liver cirrhosis registered on the waiting-list for liver transplantation for isolated 116 
cirrhosis from 01/01/2011 to 31/12/2014 were eligible. The date of 01/04/2011 was chosen 117 
because CT-scan images are included in the CHU Rennes computerized medical records only 118 
since this date. To be included, patients must have undergone an abdominal CT scan within the 3 119 
months before registering on the waiting-list for liver transplantation. Exclusion criteria were 120 
hepatocellular carcinoma as the indication for liver transplantation, multi-organ transplant, and 121 
temporary contraindication to transplantation during the follow-up. The study protocol 122 
conformed to the ethical guidelines and the 1975 Declaration of Helsinki as reflected in a priori 123 
exemption by the appropriate institutional review committee.  124 
125 
Study endpoints 126 
The primary endpoint was the occurrence of death on waiting-list for liver transplantation. As 127 
previously published [14], patients removed from the transplantation waiting list because of the 128 
worsening of their liver cirrhosis were considered as deaths. The secondary endpoint was the 129 
reliability of the measurements of transversal (TDPM) and axial (ADPM) diameters of the psoas 130 
muscle by a non-trained operator. 131 
 132 
Measurement of psoas muscle diameters 133 
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The measurements of the axial and transverse diameters of the right psoas were performed on 134 
one single CT scan image targeted on the umbilicus. We chose to assess psoas muscle diameters 135 
on umbilicus-targeted scan, because the study by Taguchi et al [21] indicated that axial and/or 136 
transversal psoas thickness at the umbilicus level was more associated with mortality than at the 137 
L3 level, in patients with metastatic urothelial carcinoma; Durand et al used this method in 138 
cirrhotic patients; the recent study by Golse et al [19] compared L3-targeted psoas muscle area to 139 
SMI, but they did not assess the predictive role of the axial or transversal diameters of the psoas 140 
muscle. The assessment was performed by one single non expert-operator (AH), a 141 
gastroenterologist fellow without any specific skill in radiology. For the first 50 patients, the 142 
measurements were checked by a radiologist specialized in Gastrointestinal Imaging, blinded of 143 
the first operator’s measurement. The operators were blinded from the demographics and clinical 144 
data including mortality on liver transplantation list. The axial diameter of psoas muscle 145 
(ADPM) was determined as the longest antero-posterior diameter and expressed in millimetre 146 
(mm) (Figure 1). The transversal diameter of the psoas muscle (TDPM) was defined as the 147 
diameter perpendicular to the axial diameter (Figure 1). Axial psoas thickness index (APTI), 148 
was expressed as mm/m, and calculated as: ADPM (mm)/height (m). Transversal psoas 149 
thickness index (TPTI) was expressed as mm/m, and calculated as: TDPM (mm)/height (m).   150 
 151 
Data collection 152 
The list of patients fulfilling the eligibility criteria was obtained by extraction from the Cristal® 153 
software, the computerized biomedicine agency database. The data were then collected by 154 
consultation of computerized files and included age, gender, body weight, height, aetiology of 155 
cirrhosis, year of cirrhosis diagnosis, presence of ascites (none, refractory), presence of hepatic 156 
encephalopathy, serum albumin, serum bilirubin, prothrombin time, serum sodium level, and 157 
serum creatinine. Clinical and laboratory data were obtained at the registration on liver 158 
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transplantation list. Child Pugh and Model for End-Stage Liver Disease (MELD) scores were 159 
calculated.160 
 161 
Statistical analysis 162 
Variables are expressed as mean ± standard deviation (SD) or percentage. Means were compared 163 
with Student t or Wilcoxon test as appropriate. Univariate analysis was performed by Cox 164 
proportional hazards model with a significance level of P<0.05. Variables significant (P<0.2) in 165 
univariate analysis were included in the multivariate analysis. To select the optimal cut-off of 166 
psoas muscle index associated with the primary endpoint, receiver operating characteristic 167 
(ROC) curve and the Youden method were used. Survival rates of subgroups of patients were 168 
calculated with Kaplan Meier method, and compared by the log-rank test. Patients transplanted 169 
and removed of transplantation list because they had an improvement of the liver disease or for 170 
personal decision were censored. Interobserver agreement of the measurements of axial (ADPM) 171 
and transversal (TDPM) diameters of the psoas muscle were analysed by kappa correlation test. 172 
Data were analysed using SPSS version 22 (SPSS Inc., Chicago, IL, USA). P value less than 173 
0.05 was considered significant with a two-tailed test. 174 
175 
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RESULTS 176 
Patients’ selection 177 
The study flow chart is shown in Figure 2. Among the 175 eligible patients, 173 were enrolled 178 
into the study and included in the final analysis.  179 
180 
Patients’ characteristics and outcomes 181 
The characteristics of the 173 included patients at the time of their registration on liver 182 
transplantation list are detailed in Table 1. The most frequent aetiology of liver cirrhosis was 183 
alcoholic (71%). Most of cirrhoses were CHILD C (66%). The mean MELD score at registration 184 
was 21.2±8.1. Forty-seven percent of cirrhoses were complicated with refractory ascites. During 185 
the mean follow-up of 5.6±6.2 month, 143 patients were transplanted (82.7%) and 13 died 186 
(7.5%). The remaining 17 patients (9.8%) were removed from the waiting-list because of disease 187 
improvement or personal decision. The mean time length on waiting-list before accessing to liver 188 
transplantation was 5.3±6.4 month. The mean time length on waiting-list before death was 189 
7.3±6.8 month.190 
191 
Relation between psoas muscle thickness and mortality192 
The univariate analysis including the patients’ characteristics at registration (gender, age, body 193 
mass index), disease variables (aetiology of cirrhosis, CHILD and MELD scores, ascites, hepatic 194 
encephalopathy, plasma bilirubin, albumin, prothrombin time, creatinine, and sodium), APTI and 195 
TPTI, is shown in Table 2. The CHILD score, the MELD score, refractory ascites, plasma 196 
creatinine and sodium, and TPTI, were significantly associated with death or exclusion of 197 
transplant list for worsening of the liver cirrhosis (Table 2). In the Cox multivariate analysis, 198 
only TPTI was independently and significantly (P<0.05) associated with mortality (Table 3). 199 
TPTI was associated with mortality: AUC=0.66 [95% confidence interval, 0.51‒0.80] (Figure  200 
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3A). According to the optimal cut-off for predicting the occurrence of death with the ROC curve, 201 
muscle mass loss was defined as TPTI<15.2 mm/m and normal muscle mass as TPTI ≥15.2202 
mm/m; then a low muscle mass was associated with higher mortality (log rank test: p<0.01)203 
(Figure 3B). Thirty-three percent of cirrhotic patients had low muscle mass at registration on 204 
waiting-list for liver transplantation, and had an overall mortality of 14% (vs. 4% in the normal 205 
muscle mass group).206 
 207 
Feasibility and interobserver agreement of the measurements of transversal (TDPM) and 208 
axial (ADPM) diameters of the psoas muscle209 
TDPM and ADPM measurements were easily performed in 100% of patients by the non-trained 210 
operator (AH). There was an almost perfect interobserver agreement: kappa coefficient 211 
correlations between the two operators-blinded TDPM and ADPM measurements (n=50) were 212 
respectively: k=0.97, p<0.0001; k=0.94, p<0.0001. This very good agreement between two 213 
operators of opposite levels of radiologic expertise suggests the reliability of the measurements 214 
by a non-trained operator.  215 
  216 
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DISCUSSION217 
In this cohort of 173 patients with liver cirrhosis on waiting-list for liver transplantation, a low 218 
TDPM measured on an umbilicus-targeted CT scan image and normalized by height (i.e. TPTI) 219 
was independently associated with mortality. The increase of 1 mm/m of the TPTI was 220 
associated with a 13% decrease in death risk. This study confirms that the assessment of muscle 221 
mass from an abdominal CT scan is an accurate method to assess mortality in liver cirrhosis 222 
patients on waiting-list for liver transplantation. Our study clearly showed that the measurement 223 
of the transversal diameter of the right psoas muscle is an easy (i.e. no need for dedicated 224 
software such as for the measurement of L3 skeletal muscle index), quick, cheap (i.e. no 225 
additional costs as abdominal CT are routinely performed before registration on liver 226 
transplantation list), and highly reproducible method, and most of all, reliable by a non-expert 227 
operator, i.e. without any specific radiological competence. These make the TDPM the elective 228 
tool, accessible for all, to assess the liver cirrhosis prognosis for the daily clinical practice of 229 
Liver Disease, Radiology, and Liver Transplantation Departments.  230 
Our study confirms the findings by Durand et al [20], but in a whole population of cirrhotic 231 
patients waiting for liver transplantation. Indeed, Durand et al only studied TPTI impact on 232 
mortality on liver transplantation waiting list in a subgroup of liver cirrhosis patients with 233 
refractory ascites and MELD<25 [19]. We found that the optimal TPTI cut-off to predict 234 
mortality was 15.22 mm/m with an AUC of 0.66. Comparable thresholds have been reported in 235 
the literature [16,20]. The recent study by Golse al [19] compared predictability for 1-year liver 236 
transplantation survival with different muscle indexes measured on a CT-scan cross section 237 
between L3 and the fourth lumbar vertebra: AUC values of right and left psoas muscle area, 238 
psoas muscles area normalized by height or body surface area, and the L3 skeletal muscle index, 239 
varied between 0.72 and 0.75. Psoas muscles area alone (below 1561 mm2 in men, or below 240 
1464 mm2 in women) best predicted survival [19]. This method looks like as less easy and more 241 
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time-consuming that the measurement of TPTI based on the right psoas only. The predictive role 242 
of the transversal diameters of the psoas muscles was not assessed by Golse et al [19]. More 243 
studies are needed in larger populations of cirrhotic patients to validate the optimal cut-off of 244 
TPTI or other muscle mass indexes, and most importantly the best indicator of muscle mass 245 
associated with long term prognosis. In all published studies, including the one presented here, 246 
the AUC values below 0.80 of the different muscle indexes suggested that the mortality 247 
prediction could be improved by associating muscle indexes prognostic with other variables 248 
associated with mortality such as refractory ascites or MELD, as previously suggested [8,20]. 249 
Indeed a MELD-psoas score outperformed MELD score alone to predict mortality on liver 250 
transplant list in subgroups restricted to patients with refractory ascites [19], and previous history 251 
of variceal haemorrhage [8]. Future studies should focus on determining whether the 252 
combination of several predictive factors, e.g. TPTI and MELD score, could improve the 253 
mortality prediction after liver transplantation. 254 
In our study, contrary to TPTI, MELD score alone was not associated (P<0.08) with mortality in 255 
the multivariable analysis. This was expected, because, since the MELD score is used to 256 
determine patients’ priority to liver transplantation, the time to access to transplantation and the257 
mortality on the waiting-list have been reduced. Therefore patients with higher MELD scores 258 
have a much shorter waiting time on transplantation list, thus better survival, than patients with 259 
lower MELD scores. However, the MELD score fails to identify patients with malnutrition or 260 
muscle mass loss, who, despite their poor prognosis related to malnutrition, are attributed a low 261 
MELD score, and therefore are not eligible for priority liver transplantation. In 2012, the French 262 
‘Agence de Biomédecine’ (Bio-Medicine Agency) reported that 20% of liver cirrhosis with a 263 
low MELD score were registered on waiting-list for liver transplantation. These included 264 
patients with cirrhosis complications, such as refractory ascites, encephalopathy, hepatorenal 265 
syndrome, hepatopulmonary syndrome, or malnutrition. In these cases, except for malnutrition, 266 
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the appeal to expert component allows deciding priority liver transplantation according to 267 
disease severity. Despite presumed muscle mass loss-related poor prognosis, malnutrition is not 268 
considered as a liver transplantation priority indication. Thanks to TPTI measurement, early 269 
identification of cirrhosis complicated with malnutrition, i.e. muscle mass loss, should allow 270 
triggering an early nutritional intervention with the aim to improve patients’ outcome on waiting 271 
list for liver transplantation.  272 
Anthropometric methods such as mid-arm muscle circumference should be abandoned because 273 
of their interobserver variability to assess muscle mass. Also in cirrhotic patients with ascites, 274 
bioimpedance analysis lacks of reliability [4-7]. However BIA-derived phase angle could be 275 
useful to assess cirrhotic patients’ prognosis [21-23]. Beside radiologic assessment of muscle 276 
mass, the clinical assessment of muscle function, e.g. by handgrip strength measurement, could 277 
be of interest because of its prognostic value [24]. This remains to be demonstrated in liver 278 
cirrhosis patients on waiting-list for liver transplantation.  279 
In our study, contrary to TPTI, APTI was not predictive of mortality. We have no clear 280 
explanation for this observation. This may be because the TDPM is more sensitive in case of 281 
catabolic situations associated to decreased protein synthesis such as malnutrition or reduced 282 
physical activity. The psoas muscle is involved in the ability of standing up, staying in the 283 
upright position, and walking. Therefore, we believe that TPTI could be a marker of muscle 284 
mass, as well as muscle function, both being related to prognosis [13-20;24-25]. This remains to 285 
be demonstrated in further studies. 286 
In this retrospective study, the mechanisms underlying the relation between low psoas muscle 287 
transversal diameter and mortality were not explored. However we could hypothesize that 288 
increased mortality is due to a defect of immune response in relation with the decrease in protein 289 
reserves. This assumption is supported by our finding (data not shown) that infectious 290 
complications are the first cause of mortality (30% of deaths) on waiting-list for liver 291 
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transplantation, and that nine out of the ten patients who died from infections had a low TDPM 292 
at registration on transplantation list. 293 
. Study limitations. The retrospective and monocentric design of the study exposed to the risk of 294 
bias. Nevertheless the characteristics of the study population were very similar to those of 295 
similar studies [17,19], and the proportion of missing data was less than 3%. Umbilicus-targeted 296 
CT scan could suffer from a lack of precision, particularly in the case of umbilical hernia, 297 
sacralisation of the L5 vertebrae, lumbar wedge fractures, and pronounced lordosis, frequent 298 
situations in the presence of ascites. However a lack of precision and a greater risk of error are 299 
also observed when analysing L3/L4-targeted images, in cases of degenerative bone diseases, i.e. 300 
vertebral osteoporosis, or lordosis related to ascites. 301 
In conclusion, the transverse psoas muscle index measured by umbilicus-targeted CT scan is a 302 
predictive factor of mortality in cirrhotic patients on waiting-list for liver transplantation. This 303 
easy, cheap, reproducible, and reliable method is routinely feasible even by non-trained staff. 304 
Prospective randomized controlled trials should assess whether a dedicated nutritional 305 
intervention combining nutrition support and physical rehabilitation in liver cirrhosis patients 306 
with low muscle mass could improve the clinical outcome of liver cirrhosis patients before and 307 
after liver transplantation.  308 
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Table 1 – Liver cirrhosis patients’ baseline characteristics, at the time of their inscription 
on liver transplantation list (n=173).  
Missing
(n)
Male / female – n (%) 0 135 (78) / 38 (22)
Age (year) – mean ± SD 0 54.7 ± 10.3
Body mass index 
– mean ± SD 
0 26.2 ± 4.7
Etiology of cirrhosis 
– n (%)
Alcohol
Metabolic
HBV
HCV
Others#
0
123 (71.1) 
13 (7.5) 
3 (1.7) 
13 (7.5) 
21 (12.1)
Duration of disease
– mean ± SD
48 ± 56
Child-Pugh score
– mean ± SD
A – n (%)
B– n (%)
C– n (%)
4
0
10.1 ± 2.2
17 (10)
41 (24)
115 (66)
Severe/ Refractory ascites 0 81 (47)
Plasma bilirubin (?mol/l) – mean ± SD 2 129 ± 54
Plasma albumin (g/l) – mean ± SD 2 31.5 ± 6.2
Prothrombin time (%) – mean ± SD 0 44 ± 19
MELD score – mean ± SD 0 21.2 ± 8.1
Plasma creatinine (?mol/l) – mean ± SD 0 85.5 ± 50.3
Plasma sodium (mmol/l) – mean ± SD 0 135 ± 5
APTI (mm/m) – mean ± SD 0 22.6 ± 3.6
TPTI (mm/m) – mean ± SD 0 17.0 ± 4.1
# Others included biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis, 
hemochromatosis. APTI, Axial Psoas Thickness Index; CI, confidence interval; HR, hazard
ratio; MELD, Model for End-Stage Liver Disease; SD, standard deviations; TPTI, Transversal 
Psoas Thickness Index.
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Table 2 – Univariate analysis of variables associated with mortality on waiting-list for liver 
transplantation according to univariate Cox analysis (n=173). Mortality was defined as the 
occurrence of death on waiting-list for liver transplantation; as previously published [14], 
patients removed from the transplantation waiting list because of the worsening of their liver 
cirrhosis were considered as deaths. 
Alive
n=160
Dead 
n=13
HR [95% CI] P-value
Male / female – n
(%)
126 (78) / 
34 (22)
9 (69) / 
4 (31)
1.38 [0.77 –
2.49]
0.28
Age (year) – mean ±
SD
54.4 ±
10.0
58.5 ± 6.0 1.06 [0.98 –
1.14]
0.13
Body mass index 
– mean ± SD 
26.0 ± 4.6 27.7 ± 5.2 1.08 [0.96 –
1.22]
0.19
Etiology of cirrhosis 
– n (%)
Alcohol
Metabolic
HBV
HCV
Others#
114 (71.3) 
12 (7.5) 3 
(1.9) 
11 (6.9) 
20 (12.5)
9 (69) 
1 (8)0 
2 (15) 
1 (8)
Reference
1.12 [0.14 –
8.96]
0.00 [0.00 -
inf]
1.24 [0.26 –
5.81]
0.53 [0.07 –
4.24]
0.97
0.49
0.93
0.98
0.78
Duration of disease
– mean ± SD
48 ± 57 39 ± 41 0.99 [0.98 –
1.00]
0.36
Child-Pugh score
– mean ± SD
A – n (%)
B– n (%)
C– n (%)
10 ± 2.2
17 (11) 
39 (24) 
104 (65)
10.6 ± 1.1
0 (0) 
2 (15) 
11 (85)
1.45 [1.08 –
1.96]
-
-
-
0.014
-
-
-
Severe/ Refractory 
ascites
49
(30.6%)
8 (61.5%) 4.34 [1.31 –
14.30]
0.016
Plasma bilirubin 
(?mol/l) – mean ±
SD
134.1 ±
159.0
68.4 ±
39.8
1.00 [0.99 –
1.01]
>0.99
Plasma albumin (g/l) 
– mean ± SD
31.5 ± 6.1 30.6 ± 6.4 0.95 [0.86 –
1.04]
0.29
Prothrombin time 
(%) – mean ± SD
44.3 ±
19.2
44.5 ±
10.2
0.97 [0.93 –
1.01]
0.11
MELD score – mean 21.2 ± 8.3 19.9 ± 3.3 1.12 [1.01 – 0.033
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± SD 1.25]
Plasma creatinine 
(?mol/l) – mean ±
SD
83.8 ±
50.3
105.3 ±
46.7
1.02 [1.01 –
1.03]
<0.001
Plasma sodium 
(mmol/l) – mean ±
SD
135 ± 5 133 ± 7 0.90 [0.81 –
0.99]
0.034
APTI (mm/m) –
mean ± SD
22.6 ± 3.5 22.4 ± 3.6 0.91 [0.76 –
1.09]
0.30
TPTI (mm/m) –
mean ± SD
17.1 ± 4.1 14.8 ± 3.8 0.84 [0.74 –
0.96]
0.009
# Others included biliary cirrhosis, autoimmune hepatitis, sclerosing cholangitis, 
hemochromatosis. APTI, Axial Psoas Thickness Index; CI, confidence interval; HR, hazard
ratio; MELD, Model for End-Stage Liver Disease; SD, standard deviations; TPTI, Transversal 
Psoas Thickness Index.
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Table 3 - Variables associated with mortality on liver transplantation list according to 
multivariate Cox analysis (n=173). For continuous variables (Transversal Psoas Thickness 
Index (TPTI), Model for End-Stage Liver Disease (MELD) score, and plasma sodium), the 
hazard ratio (HR) are expressed for 1-point increase.
 
 
 
 
 
 
Variables HR 95% confidence interval P-value
TPTI per mm/m 0.87 0.76 – 0.99 0.034
MELD score per unit 1.10 0.99 – 1.22 0.08
Plasma sodium per mmol/l 0.94 0.85 – 1.04 0.26
Refractory ascites yes vs. no 2.93 0.83 – 10.30 0.094
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Figures legends 
Figure 1 - Right psoas muscle diameters measured on a CT scan image targeted on the 
umbilicus. Axial diameter of the psoas muscle (ADPM) is represented by the dotted line. 
Transversal diameter of the psoas muscle (TDPM) is represented by the full line.
Figure 2 - Study flow chart.
Figure 3 - Predictive value of Transversal Psoas Thickness Index (TPTI) on mortality of liver 
cirrhosis patients on waiting-list for liver transplantation (n=173). (A) Area under the receiver 
operating characteristic curves (AUC). A low TPTI is associated with increased mortality. 
AUC=0.66 [95% confidence interval, 0.51‒0.80]. (B) Kaplan Meier curves indicating the 
probability of survival in patients with  muscle mass loss (green line) or without muscle mass loss 
(blue line). Muscle mass loss was defined as Transversal Psoas Thickness Index (TPTI) <15.2
mm/m, as determined in (A); n=173; log rank test, P<0.01.
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Figure 2 
 
 
346 patients screened 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 patients not included because of 
missing CT scan 
         175  eligible patients evaluated 
2 patients secondly excluded : 
? still on the waiting-list for liver  
transplantation at the time of data 
collection (n=1) 
?  temporary contraindication  to liver 
transplantation (n=1) 
 
173 patients included for analysis 
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Figure 3 
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